NCT02642094

Aging Mammary Stem Cells and Breast Cancer Prevention

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: LuZhe Sun · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

Detailed description

A non-randomized, open-label, phase II, window of opportunity trial will be carried out to see if a 5-7 day rapamycin treatment can reduce malignant markers and aberrant MaSC number

Conditions

• Cancer of Breast

Interventions

Type	Name	Description
DRUG	Rapamycin	Low dose of rapamycin at 2 mg/day for -5-7 days of treatment

Timeline

• Start date: 2016-07-01
• Primary completion: 2022-03-01
• Completion: 2022-05-01
• First posted: 2015-12-30
• Last updated: 2023-12-05
• Results posted: 2023-12-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study